Pharmaceuticals
CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients
* Sugemalimab is the world's first PD-L1 monoclonal antibody that when administered along with chemotherapy improved overall survival of first-line metastatic squamous and non-squamous non-small cell lung cancer patients in a statistically significant and clinically meaningful manner * Surviv...
2022-01-19 08:05
4575
Lynk Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Study of LNK01001 in Patients with Ankylosing Spondylitis
HANGZHOU, China, Jan. 19, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced today that the first patient has been dosed with LNK01001 in its Phase II clinical trial targeting ankylosing spondyli...
2022-01-19 08:00
4359
Servier Group Reports Financial Year 2020/2021 Annual Results, R&D Strategy and Pipeline
- Consolidated revenue of €4.725 billion, up +4.3% at constant rates (+0.8% at current rates) - Revenue for brand-name medicines of €3.306 billion +4.8% at constant rates (+0.6% at current rates) and €1.419 billion for the generics +2.9% at constant rates (+1.1% at current rates) - An accelerat...
2022-01-18 20:00
2695
Ascletis Announces Signing of Ritonavir Tablet Purchase Agreement with Phokam Pharmaceutical Import-Export Co., Ltd of Laos
HANGZHOU and SHAOXING, China, Jan. 18, 2022 /PRNewswire/ -- Ascletis Pharma Inc. ("Ascletis") (HKEX: 1672) today announces signing of the ritonavir tablet purchase agreement between Phokam Pharmaceutical Import-Export Co., Ltd (as buyer) ofLaos and Ascletis Pharmaceuticals Co., Ltd. (as seller), ...
2022-01-18 18:00
3816
Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into Clinical Trials
WILMINGTON, Del., Jan. 18, 2022 /PRNewswire/ -- Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. today announced the establishment of Dermaliq Therapeutics, Inc (Dermaliq), a newly formedDelaware -based pharmaceutical development company, and the signing of aUSD 1...
2022-01-18 17:00
2976
Baheya Foundation, Egypt's Premier Destination for Breast Cancer, Adopts Lunit AI to Enhance Early Screening
SEOUL, South Korea, Jan. 18, 2022 /PRNewswire/ -- Lunit today announced a Reference Site Agreement with Baheya Foundation for Early Detection & Treatment of Breast Cancer, a non-profit organization based inEgypt that treats women with breast cancer. According to the agreement, the foundation will...
2022-01-18 13:00
2490
Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 2b Clinical Trial Evaluating XW003, its Lead GLP-1 Drug Candidate, for the Treatment of Obesity
HANGZHOU, China and SAN FRANCISCO, Jan. 18, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the initiation of patient dosing in its Phase2b clinica...
2022-01-18 08:00
4167
CStone announced two key phase 3 registrational clinical trials of sugemalimab completed patient enrollment
* Both trials investigate first-line treatment with sugemalimab combined with chemotherapy in patients with metastatic gastric adenocarcinoma (GC)/gastro-esophageal junction (GEJ) adenocarcinoma or esophageal squamous cell carcinoma (ESCC) * A significant milestone in our pipeline development...
2022-01-18 08:00
5261
Seegene's Allplex™ SARS CoV-2 FluA/FluB/RSV Assay approved under Health Canada's Interim Order
SEOUL, South Korea, Jan. 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostic company, announced it has received approval of its Allplex™ SARS CoV-2 FluA/FluB/RSV Assay under Health Canada's Interim Order onJanuary 11. Seegene's Allplex™ SARS CoV-2 Flu...
2022-01-17 20:00
3494
Seegene Continues to Support Israel's Effort to Manage the Omicron Variant With Timely Delivery of Five Million Tests
SEOUL, South Korea, Jan. 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today that it has delivered over five million COVID-19 tests toIsrael to help detect and mitigate the spread of the Omicron variant. The company sent 1.7 mill...
2022-01-17 20:00
3312
Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B
-- Estimated 1.59 million chronic hepatitis B (CHB) patients in the U.S. -- Interim results of the Phase IIb trial conducted on CHB patients in China showed that in patients with the baseline hepatitis B surface antigen (HBsAg) level ≤ 500 IU/mL, approximately 19% (3/16) of patients in the treatm...
2022-01-17 18:12
5230
The Philippines Has Approved ReCOV For Phase II/III Cinical Trial
* Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III Clinical Trial * ReCOV induced high levels of neutralizing antibodies against SARS-CoV-2 and Variants of Concern such as Omicron and Delta * Rhecogen , a subsidiary focused on mRNA vaccines of th...
2022-01-17 16:57
3922
CStone announces the clinical data from registrational study of Sugemalimab in stage III non-small cell lung cancer published in The Lancet Oncology
SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the registrational clinical...
2022-01-15 08:35
6972
CStone announces the registrational clinical study results of sugemalimab in stage IV non-small cell lung cancer published in The Lancet Oncology
SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that results of the GEMSTONE-302...
2022-01-15 08:31
6397
French Consul General in Guangzhou led a delegation to visit Biosyngen in China-Singapore Guangzhou Knowledge City
GUANGZHOU, ChinaJan. 15, 2022 /PRNewswire/ -- On the afternoon of January 14th, Mr. Sylvain FOURRIERE, Consul General ofFrance in Guangzhou, and officers from consulates general of 9 countries includingBritain, Canada and Switzerland visited China-Singapore Guangzhou Knowledge City andSingapore -...
2022-01-15 08:00
7103
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
Results from ongoing testing and monitoring of COVID-19 variants shows the rapid microfluidic test detects Omicron at a comparable sensitivity to other variants LONDON, Jan. 14, 2022 /PRNewswire/ -- LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced tha...
2022-01-14 19:18
3776
Everest Medicines Enters into a Global Licensing Agreement to Develop and Commercialize Singapore's Experimental Drug Development Centre's 3CL Protease Inhibitors as Potentially Best-in-Class COVID-19 Oral Antiviral Treatments Worldwide
SHANGHAI, Jan. 14, 2022 /PRNewswire/ -- Everest Medicines
2022-01-14 08:00
6455
Accuredit Therapeutics and N1 Life Form a Joint Venture Named 'Napoltec', Dedicated to the Development of Therapeutic Drug Delivery Systems and Pressing Ahead Clinical Translation
SUZHOU, China, Jan. 13, 2022 /PRNewswire/ -- Accuredit Therapeutics (Suzhou) Co., Ltd. (hereinafter referred to as Accuredit), an emerging company based on new generations of safe and highly targeted gene editing therapies, and N1 Life, a biotech company focused on developing cutting-edge drug de...
2022-01-13 13:33
4447
NeuroAiD(TM)II holds promise as a safe add-on therapy to standard Alzheimer Disease symptomatic treatments and may have a disease modifying effect by delaying disease progression
SINGAPORE, Jan. 13, 2022 /PRNewswire/ -- Moleac is pleased to announce the release of the ATHENE study results, published in the Journal of the American Medical Director Association (JAMDA)1. Alzheimer's Disease (AD) and other dementias cause a heavy economic and public healthcare burden worldw...
2022-01-13 12:32
4679
Enrollment Completed in Phase II Clinical Study of KN026 Combined with KN046
* Interim analysis expected in the second quarter of 2022 SUZHOU, China, Jan. 13, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase II clinical study of KN026 (HER2 bispecific antibody) combined with KN046 (PD-L1/CTLA-4 bispecific antibody) (KN026-203) has su...
2022-01-13 10:46
4004
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 281 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 267 media titles]
2026-09-30 10:50
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 267 media titles]
2026-10-01 10:00
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
22708
Toshiba Information Equipment (Philippines) Celebrates 30th Anniversary and First Shipment from Expanded Nearline HDD Production Line
2026-10-02 21:14
8456
